A Randomized Phase II Study of Androgen Deprivation Combined With IMC-A12 Versus Androgen Deprivation Alone for Patients With New Hormone-Sensitive Metastatic Prostate Cancer
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 04 Jul 2017
At a glance
- Drugs Cixutumumab (Primary) ; Bicalutamide; Goserelin; Leuprorelin; Leuprorelin
- Indications Prostate cancer
- Focus Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 30 May 2014 Primary endpoint 'Prostate specific antigen response rate' not met.
- 30 May 2014 Results presented at the 50th Annual Meeting of the American Society of Clinical Oncology.